- Recent Funding
- Investors
- Third Rock Ventures
Third Rock Ventures portfolio
Third Rock Ventures has 6 portfolio companies on record at Recent Funding, with 2 investments in the last 12 months.
About this page
It is a venture capital firm based in Boston, US, founded in 2007. It led 7 of the 12 rounds it joined. Its most recent investment on record is Flare Therapeutics's $85M Series B+ round in June 2026, which it led, alongside Nextech Invest. By category, its portfolio leans toward Health and bio (6). It has co-invested with Nextech Invest, Invus and Boxer Capital, most often Nextech Invest (5 rounds).
About Third Rock Ventures
What Third Rock Ventures invests in
- Health and bio · 6 · 100%
Third Rock Ventures recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series B+ · $85M · lead | Nextech Invest (lead) | ||
| Series A · $165M · lead | Dexcel Pharma (lead), Pictet Private Equity Investors S.A., Bain Capital Life Sciences +2 | ||
| Series B+ · $132M | Qatar Investment Authority, Omega Funds, Alexandria Venture Investments +3 | ||
| Series A · $120M · lead | Biotechnology Value Fund (lead), Bain Capital Life Sciences (lead), Perceptive Advisors +1 | ||
| Series B+ · $55M | Wellington Management, Janus Henderson Investors, Bristol-Myers Squibb +3 | ||
| Series A · $90M · lead | Omega Funds, F-Prime Capital | ||
| Series B+ | Novartis Venture Fund, GordonMD Global Investments (lead), Memorial Sloan - Kettering Cancer Center +6 | ||
| Series B+ · $150M | LifeSci Venture Partners, Creacion Ventures, Invus +6 |
How Third Rock Ventures invests
Third Rock Ventures portfolio companies
FFlare Therapeutics$85MSeries B+ · Jun 2026
SSyremis Therapeutics$165MSeries A · Dec 2025
AARTBIO$132MSeries B+ · Jul 2025
MMerida Biosciences$120MSeries A · May 2025
AAsher Bio$55MSeries B+ · Apr 2024
MMOMA Therapeutics$150MSeries B+ · May 2022
| Company | Round with Third Rock Ventures | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $85M · lead | $167M | Jun 30, 2026 Series B+ |
Health and bio |
Series A · $165M · lead | $165M | Dec 18, 2025 Series A |
Health and bio |
Series B+ · $132M | $245M | Jul 29, 2025 Series B+ |
Health and bio |
Series A · $120M · lead | $120M | May 7, 2025 Series A |
Health and bio |
Series B+ · $55M | $218M | Apr 16, 2024 Series B+ |
Health and bio |
Series B+ · $150M | $236M | May 10, 2022 Series B+ |
Most frequent co-investors
NNextech Invest5 shared rounds · last Jun 30, 2026
IInvus5 shared rounds · last Mar 22, 2023
BBoxer Capital4 shared rounds · last Apr 16, 2024
GGV2 shared rounds · last Dec 18, 2025
BBain Capital Life Sciences2 shared rounds · last Dec 18, 2025
FF-Prime Capital2 shared rounds · last Jul 29, 2025
OOmega Funds2 shared rounds · last Jul 29, 2025
AAlexandria Venture Investments2 shared rounds · last Jul 29, 2025
RRA Capital Management2 shared rounds · last Apr 16, 2024
WWellington Management2 shared rounds · last Apr 16, 2024
JJanus Henderson Investors2 shared rounds · last Apr 16, 2024
PPavilion Capital2 shared rounds · last Mar 22, 2023
Similar investors
AAdage Capital Management6 companies · 4 deals in 12 mo
HHealthier Capital6 companies · 4 deals in 12 mo
SSymBiosis6 companies · 4 deals in 12 mo
UUC Investments6 companies · 4 deals in 12 moAAbingworth6 companies · 3 deals in 12 mo
HHBM Healthcare Investments6 companies · 3 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 12 rounds on Recent Funding that name Third Rock Ventures. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Third Rock Ventures, which is a subset of its real portfolio. API: /api/v1/investors/third-rock-ventures (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy